1
|
Lu Q, Zhou L, Wang Z, Li X, Ding L, Qiu Y, Guo P, Ye C, Fu S, Wu Z, Liu Y. Baicalin Alleviate Apoptosis via PKC-MAPK Pathway in Porcine Peritoneal Mesothelial Cells Induced by Glaesserella parasuis. Molecules 2022; 27:molecules27165083. [PMID: 36014323 PMCID: PMC9414593 DOI: 10.3390/molecules27165083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2022] [Revised: 07/23/2022] [Accepted: 07/26/2022] [Indexed: 11/16/2022] Open
Abstract
Glaesserella parasuis (GPS), a causative agent of Glässer’s disease, is thought to be the main fatal cause of peritonitis in swine, thus resulting in high mortality and morbidity and significant economic losses to the swine industry. However, the mechanisms of GPS infection-induced apoptosis and possible therapeutic pathway for GPS infection in peritonitis remain unclear. Baicalin has important biological functions during disease treatment, such as antiviral, bacterial inhibition, anti-apoptosis, and anti-inflammatory. However, whether baicalin has anti-apoptotic effects during the process of GPS infection in peritonitis is unclear. In the present study, the anti-apoptotic effect and mechanisms of baicalin in GPS infection-induced apoptosis were investigated in porcine peritoneal mesothelial cells (PPMC). The results showed that baicalin could inhibit the apoptosis rate occurrence of PPMC induced by GPS to various degrees and inhibit the expression of apoptosis-related genes and cleaved caspase-3. Meanwhile, baicalin significantly antagonized the expression of p-JNK, p-p38, and p-ERK induced by GPS in PPMC. These findings for the first time demonstrate that baicalin exerted the effect of antagonizing GPS induced apoptosis in PPMC by inhibiting the activation of the PKC-MAPK pathway and could be a therapeutic option in the management of GPS infection.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Yu Liu
- Correspondence: or ; Tel.: +86-27-83956175; Fax: +86-27-83956175
| |
Collapse
|
2
|
Wang L, Long M, Wang M, Peng S, Chen G, Zhou J, Ou C. Trigeminal neuralgia causes neurodegeneration in rats associated with upregulation of the CD95/CD95L pathway. Mol Pain 2021; 16:1744806920908092. [PMID: 32013712 PMCID: PMC7054737 DOI: 10.1177/1744806920908092] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Objectives To explore the effects of trigeminal neuralgia on neurodegeneration
in rats and the underlining mechanism. Methods Sixty adult male Sprague Dawley rats were divided randomly into
Chronic Constriction Injury of the Rat’s Infraorbital Nerve
(ION-CCI) group and sham group (n = 30). Right
suborbital nerve was ligated in ION-CCI group to establish a
trigeminal neuralgia model. In sham group, suborbital nerve was
exposed without ligation. Pain thresholds were measured before
surgery and 1, 7, 15, and 30 days after surgery
(n = 10). Morris water maze tests
(n = 10) were conducted at 1, 15, and
30 days after surgery to evaluate the changes in learning and
memory ability of rats. At 5, 19, and 34 days after surgery,
serum S100β protein concentration and hippocampal Aβ1-42 protein
expression were detected by enzyme-linked immunosorbent assay;
total tau protein expression was detected by Western blotting;
changes of neurons in hippocampus were observed by Nissl
staining; and the expression of ser404p-tau, cluster
of differentiation (CD)95, CD95L, and cleaved caspase-3 proteins
was detected by immunofluorescence and Western blotting. Results Hyperalgesia occurred in ION-CCI group, and mechanical pain
threshold decreased significantly
(P < 0.05). On the 15th and 30th days after
surgery, ION-CCI group showed lower learning and memory ability
than sham group (P < 0.05). Serum S100β
protein concentration, hippocampal A β1-42, and
ser404p-tau protein expression increased in the
ION-CCI group 19 and 34 days after surgery
(P < 0.05), hippocampal CD95 expression
increased in the ION-CCI group after surgery
(P < 0.05), hippocampal CD95L expression
increased at 19 and 34 days after surgery
(P < 0.05), and cleaved caspase-3 expression
increased at 5 and 19 days after surgery
(P < 0.05). Nissl bodies in ION-CCI group
decreased significantly at 15 days after surgery. The expression
of cleaved caspase-3 protein in ION-CCI group was positively
correlated with the expression of CD95 and CD95L
(P < 0.05). Conclusions Trigeminal neuralgia may lead to neuronal inflammation and neuronal
apoptosis associated with upregulation of CD95/CD95L expression,
thus causing neurodegeneration.
Collapse
Affiliation(s)
- Lu Wang
- Department of Anesthesiology, The Affiliated Hospital of Southwest Medical University, Luzhou, P.R. China.,Laboratory of Anesthesiology, Affiliated Hospital of Southwest Medical University, Luzhou, P.R. China
| | - Menghong Long
- Department of Anesthesiology, The Affiliated Hospital of Southwest Medical University, Luzhou, P.R. China.,Laboratory of Anesthesiology, Affiliated Hospital of Southwest Medical University, Luzhou, P.R. China
| | - Maohua Wang
- Department of Anesthesiology, The Affiliated Hospital of Southwest Medical University, Luzhou, P.R. China
| | - Shuangchun Peng
- Department of Anesthesiology, The Affiliated Hospital of Southwest Medical University, Luzhou, P.R. China.,Laboratory of Anesthesiology, Affiliated Hospital of Southwest Medical University, Luzhou, P.R. China
| | - Guangxiang Chen
- Department of Radiology, The Affiliated Hospital of Southwest Medical University, Luzhou, P.R. China
| | - Jun Zhou
- Department of Anesthesiology, The Affiliated Hospital of Southwest Medical University, Luzhou, P.R. China
| | - Cehua Ou
- Pain Department, The Affiliated Hospital of Southwest Medical University, Luzhou, P.R. China
| |
Collapse
|
3
|
Kalvelage C, Zacharowski K, Bauhofer A, Gockel U, Adamzik M, Nierhaus A, Kujath P, Eckmann C, Pletz MW, Bracht H, Simon TP, Winkler M, Kindgen-Milles D, Albertsmeier M, Weigand M, Ellger B, Ragaller M, Ullrich R, Marx G. Personalized medicine with IgGAM compared with standard of care for treatment of peritonitis after infectious source control (the PEPPER trial): study protocol for a randomized controlled trial. Trials 2019; 20:156. [PMID: 30832742 PMCID: PMC6399861 DOI: 10.1186/s13063-019-3244-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2018] [Accepted: 02/08/2019] [Indexed: 12/29/2022] Open
Abstract
Background Peritonitis is responsible for thousands of deaths annually in Germany alone. Even source control (SC) and antibiotic treatment often fail to prevent severe sepsis or septic shock, and this situation has hardly improved in the past two decades. Most experimental immunomodulatory therapeutics for sepsis have been aimed at blocking or dampening a specific pro-inflammatory immunological mediator. However, the patient collective is large and heterogeneous. There are therefore grounds for investigating the possibility of developing personalized therapies by classifying patients into groups according to biomarkers. This study aims to combine an assessment of the efficacy of treatment with a preparation of human immunoglobulins G, A, and M (IgGAM) with individual status of various biomarkers (immunoglobulin level, procalcitonin, interleukin 6, antigen D-related human leucocyte antigen (HLA-DR), transcription factor NF-κB1, adrenomedullin, and pathogen spectrum). Methods/design A total of 200 patients with sepsis or septic shock will receive standard-of-care treatment (SoC). Of these, 133 patients (selected by 1:2 randomization) will in addition receive infusions of IgGAM for 5 days. All patients will be followed for approximately 90 days and assessed by the multiple-organ failure (MOF) score, by the EQ QLQ 5D quality-of-life scale, and by measurement of vital signs, biomarkers (as above), and survival. Discussion This study is intended to provide further information on the efficacy and safety of treatment with IgGAM and to offer the possibility of correlating these with the biomarkers to be studied. Specifically, it will test (at a descriptive level) the hypothesis that patients receiving IgGAM who have higher inflammation status (IL-6) and poorer immune status (low HLA-DR, low immunoglobulin levels) have a better outcome than patients who do not receive IgGAM. It is expected to provide information that will help to close the knowledge gap concerning the association between the effect of IgGAM and the presence of various biomarkers, thus possibly opening the way to a personalized medicine. Trial registration EudraCT, 2016–001788-34; ClinicalTrials.gov, NCT03334006. Registered on 17 Nov 2017. Trial sponsor: RWTH Aachen University, represented by the Center for Translational & Clinical Research Aachen (contact Dr. S. Isfort). Electronic supplementary material The online version of this article (10.1186/s13063-019-3244-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Christina Kalvelage
- Center for Translational and Clinical Research Aachen, RWTH Aachen University, Pauwelsstr. 30, 52074, Aachen, Germany
| | - Kai Zacharowski
- Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Frankfurt, Germany
| | - Artur Bauhofer
- Corporate Medical Affairs, Biotest AG, Landsteinerstr. 5, 63303, Dreieich, Germany
| | - Ulrich Gockel
- Medical Affairs Central Europe, Biotest AG, Landsteinerstr. 5, 63303, Dreieich, Germany
| | - Michael Adamzik
- Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, Ruhr-Universität Bochum, In der Schornau 23-25, 44892, Bochum, Germany
| | - Axel Nierhaus
- Department of Intensive Care Medicine, University Hospital Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany
| | - Peter Kujath
- Department of Surgery, University of Schleswig-Holstein, Ratzeburger Allee 160, 23538, Lübeck, Germany
| | - Christian Eckmann
- Department of General, Visceral, and Thoracic Surgery, Klinikum Peine Academic Hospital of Medical University Hannover, Virchowstraße 8h, 31226, Peine, Germany
| | - Mathias W Pletz
- Center for Infectious Diseases and Infection Control, Jena University Hospital, Erlanger Allee 101, 07747, Jena, Germany
| | - Hendrik Bracht
- Department of Anaesthesiology, University Ulm, Albert Einstein Allee 23, 89081, Ulm, Germany
| | - Tim-Philipp Simon
- Department of Intensive Care and Intermediate Care, University Hospital RWTH Aachen, Pauwelsstr.30, 52074, Aachen, Germany
| | - Michael Winkler
- Department of General, Visceral and Transplantation Surgery, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany
| | - Detlef Kindgen-Milles
- Department of Anaesthesiology, Düsseldorf University Hospital, Moorenstr. 5, 40225, Düsseldorf, Germany
| | - Markus Albertsmeier
- Department of Anaesthesiology, Ludwig-Maximilians-University of Munich, Marchioninistrasse 15, 81377, Munich, Germany
| | - Markus Weigand
- Department of Anesthesiology, Heidelberg University Hospital, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany
| | - Björn Ellger
- Department of Anesthesiology, Intensive Care and Pain Medicine, Klinikum Westfalen, Am Knappschaftskrankenhaus 1, 44309, Dortmund, Germany
| | - Maximilian Ragaller
- Department of Anesthesiology and Intensive Care Medicine, Technical University Dresden, Fetscherstraße 74, 01307, Dresden, Germany
| | - Roman Ullrich
- Department of Anaesthesia, Critical Care and Pain Medicince, Medical University of Vienna, Währinger Gürtel 18-20 / 9i, 1090, Vienna, Austria
| | - Gernot Marx
- Department of Intensive Care and Intermediate Care, University Hospital RWTH Aachen, Pauwelsstr.30, 52074, Aachen, Germany.
| |
Collapse
|
4
|
Vlasov AP, Salahov EK, Shibitov VA, Vlasov PA, Bolotskih VA. [Integrated approach to correction enteral insufficiency in early postoperative period]. Khirurgiia (Mosk) 2016:52-58. [PMID: 27271720 DOI: 10.17116/hirurgia2016552-58] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
AIM The purpose of the research was to study the effectiveness of enteral insufficiency correction at an acute peritonitis by applying minimally invasive techniques, electrical stimulation and rehabilitation of the bowel and abdominal intestine using Remaxol drug. MATERIAL AND METHODS The analysis of the results of clinical and laboratory examination and treatment of 110 patients with acute diffuse peritonitis. In the comparison group (62 patients) in the early postoperative period applied standardized treatment, including software reorganization of the abdominal cavity, in the study group (48 patients) -- a comprehensive treatment that includes software laparoscopic sanation abdominal electrical stimulation of the duodenum, and intra-abdominal (single dose, 200 ml), and intracolonic (200 ml, 2 times daily) administration Remaxol. It was noted a significant improvement in treatment outcomes, including reduced mortality by 2.3 times, the shortening of hospital stay by 1.3 times. RESULTS The major component of the positive effect of the developed scheme of therapy is its ability to promptly arrest the effects of enteral insufficiency, maintain the functional status of the liver. The relatively rapid recovery of motor and intestinal barrier function leads to a lowering of enteral insufficiency syndrome, which along with increased liver detoxification ability underlies the significant reduction of endogenous intoxication in three days. An important contribution to the effectiveness of the treatment makes intra and intracolonic administration Remaxol. The drug, possessing antioxidant, antihypoxic, hepatoprotective effects, contributes to the relatively rapid improvement of the barrier function of the peritoneum and intestines, detoxification ability of the liver recovery that significantly contributes to the relief of endogenous intoxication.
Collapse
Affiliation(s)
- A P Vlasov
- N.P. Ogarev Mordovia State University, Russia
| | - E K Salahov
- N.P. Ogarev Mordovia State University, Russia
| | | | - P A Vlasov
- N.P. Ogarev Mordovia State University, Russia
| | | |
Collapse
|
5
|
Vlasov AP, Trofimov VA, Grigorieva TI, Shibitov VA, Vlasov PA. [Enteral distress syndrome in surgery: definition, pathogenesis, diagnosis]. Khirurgiia (Mosk) 2016:48-53. [PMID: 27905373 DOI: 10.17116/hirurgia20161148-53] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
It was performed a comprehensive experimental and clinical study of functional and metabolic status of the intestine in acute peritonitis, pancreatic necrosis, acute intestinal obstruction. We obtained objective data of impaired barrier function based on levels of toxins in arterial and mesenteric venous blood. Association of organ and organismic homeostatic changes was revealed. It was proved an important role of membrane-destabilizing processes in intestinal epithelium as a cause of enteral insufficiency. Leading trigger mechanisms of lipid metabolic disorders were determined. Enteral distress syndrome was determined as pathological response to acute abdominal surgical diseases. Enteral distress syndrome is a complex of pathological processes due to membrane-destabilizing mechanisms, impaired intestinal barrier function followed by progression of endogenous intoxication. This syndrome significantly aggravates the course of acute surgical abdominal diseases.
Collapse
Affiliation(s)
- A P Vlasov
- Ogarev Mordovian State University, Saransk, Russia
| | - V A Trofimov
- Ogarev Mordovian State University, Saransk, Russia
| | | | - V A Shibitov
- Ogarev Mordovian State University, Saransk, Russia
| | - P A Vlasov
- Ogarev Mordovian State University, Saransk, Russia
| |
Collapse
|